All News
Filter News
Found 270 articles
-
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
11/2/2023
Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the third quarter of 2023 and provided a general business update.
-
Karuna Therapeutics to Present at Upcoming November 2023 Investor Conferences
11/1/2023
Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the following upcoming investor conferences.
-
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
11/1/2023
Karuna Therapeutics, Inc. announced it will be presenting new efficacy, safety, and tolerability analyses from its EMERGENT program evaluating KarXT in adults with schizophrenia at the upcoming Neuroscience Education Institute Congress, to be held November 9-12, 2023, in Colorado Springs, CO.
-
Rapport Therapeutics Appoints Chief Financial Officer
10/30/2023
Rapport Therapeutics, Inc. today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
-
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
10/19/2023
Karuna Therapeutics, Inc. (NASDAQ: KRTX) today announced that it will host a live conference call and webcast on Thursday, November 2, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and provide a general business update.
-
At the six-month follow-up, about 40% of patients treated with Newron Pharmaceuticals’ evenamide improved so much that they no longer meet the Phase II study’s original eligibility criteria.
-
Here’s how some biopharmas have managed to gain funding despite a falloff in investment in the sector. Hint: Positive late-stage data is a key factor.
-
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
10/4/2023
Karuna Therapeutics, Inc. announced it will be presenting new secondary efficacy, safety and tolerability, and pooled cognition data from its EMERGENT clinical program evaluating KarXT in schizophrenia.
-
If approved by the FDA, Karuna Therapeutics’ investigational agonist of muscarinic acetylcholine 1 receptors M1 and M4 would provide the first new mechanism of action for schizophrenia patients in decades.
-
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
9/28/2023
PureTech Health plc, a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics, Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia.
-
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
9/28/2023
Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia.
-
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
9/5/2023
PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research grant, to use their combined AI tools to design new drugs for mental health disorders.
-
Karuna Therapeutics to Present at Upcoming September 2023 Investor Conferences
8/30/2023
Karuna Therapeutics, Inc. announced that management will present at the following upcoming investor conferences.
-
PureTech Health plc – 2023 Half-Year Report
8/29/2023
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2023.
-
Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform
8/23/2023
Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, announced that it has raised $150 million in Series B funding.
-
With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.
-
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
8/3/2023
Karuna Therapeutics, Inc. announced financial results for the second quarter of 2023 and provided a general business update.
-
Karuna Therapeutics Announces Leadership Appointments - August 03, 2023
8/3/2023
Karuna Therapeutics, Inc. announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer.
-
Ulotaront failed to meet primary endpoints in two studies. The companies said high COVID-19 placebo effect “may have masked molecule’s therapeutic effect” and plan to discuss next steps with the FDA.
-
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
7/20/2023
Karuna Therapeutics, Inc. announced that it will host a live conference call and webcast on Thursday, August 3, 2023 at 8:00 a.m. ET to review second quarter 2023 financial results and provide a general business update.